What is brenipatide, and how is it different from tirzepatide and retatrutide?

Brenipatide is Lilly’s investigational drug LY3537031, which activates both GIP and GLP-1 receptors. Tirzepatide also activates those two receptors, whereas retatrutide activates GIP, GLP-1 and glucagon receptors. These names describe different molecules, not different brands of one drug. Receptor count alone cannot rank how well they work: exposure, receptor activity, the population studied and the outcome being measured all matter. Weight-loss results from one compound cannot be assigned to another because their targets overlap.[1][2]

Brenipatide’s clinical development is particularly interesting because it includes alcohol use disorder, depression, bipolar disorder and smoking relapse prevention. That makes it relevant to research on how metabolic signaling might influence behavior and mental health, rather than simply another entry in a weight-loss ranking. However, a trial announcement is not proof of an effective addiction or psychiatric treatment. Lilly’s pipeline and trial descriptions establish what is being investigated; they do not establish that brenipatide is a better version of tirzepatide or that it produces retatrutide-like weight loss.[1][3][4]